Novo Nordisk Annual Report 2021
Contents Introducing Novo Nordisk
Strategic Aspirations
Key risks
Management
Consolidated statements
Additional information.
Novo Nordisk Annual Report 2021 15
F
Our social responsibility:
being respected for adding value to society
We are driven by our purpose to defeat diabetes and other
serious chronic diseases including obesity, haemophilia and
growth hormone disorders. While innovation is our core
contribution to this fight, we know that complex inequalities in
healthcare remain the biggest barrier. By playing an active role
in improving access to innovative and affordable solutions for
people with chronic conditions across the globe, our aim is to
deliver real change in the communities we serve.
Rebecca Commanda has type 2
diabetes and lives in Canada
With approximately 537 million adults in the world living with
diabetes - a figure that is projected to rise to 783 million by
2045 if no action is taken - our Defeat Diabetes strategy is a
cornerstone of our social responsibility work. We are striving to
bend the curve of diabetes through product innovations that will
improve lives, while at the same time working with partners to
prevent the rise of new cases of both type 2 diabetes and obesity,
as well as ensuring that vulnerable patients in every country can
access and afford the care they need. With a growing health
challenge of this magnitude, we know that we are nowhere close
to defeating diabetes, but we are committed to doing nothing
short of that and fortunately, we are not alone in this fight.
Improving access to life-changing care in low-
and middle-income countries
Given our dedication to improve the lives of people with
diabetes and other serious chronic diseases, including obesity,
haemophilia and growth hormone disorders, we strive not
only to identify new innovative treatments but also to support
a strong healthcare system that ensures patient access and
affordability for the medications they need.
We recognise that access to affordable medicines is a challenge
for many people, and not only in low-income countries. This is
why we are expanding our initiatives and partnerships to reach
more underserved people with affordable care worldwide. Each
initiative is tailored to the local context, unmet needs and health
system challenges. Our access and affordability efforts now
reach more than 5 million patients out of the 34.6 million who
use our diabetes care products around the world.
Ensuring not only that access to care for patients is achieved but
that it is done in a sustainable manner is the most important
consideration in our initiatives. This is why we always aim to
5+ million
patients reached via our access and affordability
efforts, corresponding to approximately
14%
of all our diabetes patients
include local health authorities, partners and civil society in all
implementation activities. Shared ownership and involvement are
critical to value creation for the end users and the health system,
as well as for the sustainability of the solution.
The Changing Diabetes® in Children partnership is one example of
this work. The programme has to date provided free care to nearly
32,000 children and youth living with type 1 diabetes in low- and
middle-income countries, putting it almost one-third along the way
towards achieving our aspiration of reaching 100,000 children in
low-resource settings by 2030. The partnership is present in 18
countries, following the addition of Ghana, Indonesia, Pakistan and
Peru in 2021. Five more countries (Mozambique, Rwanda, Malawi,
Jordan and Lebanon) are launching in early 2022 as part of an
expanded partnership project with the World Diabetes Foundation.
For the many other vulnerable people who are living with both
type 1 and type 2 diabetes and who are struggling to access the
care they need, we are leveraging our global organisation and
using our presence on the ground to develop and implement
country-based solutions. An example of this is the iCARE to Defeat
Diabetes strategy launched in our Sub-Saharan business unit.View entire presentation